Published in J Allergy Clin Immunol on July 01, 2002
Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med (2010) 3.24
Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy (2010) 1.35
Developmentally regulated expression, alternative splicing and distinct sub-groupings in members of the Schistosoma mansoni venom allergen-like (SmVAL) gene family. BMC Genomics (2008) 1.32
The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy (2005) 1.28
Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol (2013) 1.14
Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils. Int Arch Allergy Immunol (2012) 1.06
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol (2014) 1.05
Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine (2011) 1.01
Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy (2012) 0.95
Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy (2012) 0.92
Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine (2016) 0.88
Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine (2011) 0.87
Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol (2012) 0.87
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One (2012) 0.85
The expression of CD123 can decrease with basophil activation: implications for the gating strategy of the basophil activation test. Clin Transl Allergy (2016) 0.84
Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol (2010) 0.83
Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy. EBioMedicine (2017) 0.81
Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol (2014) 0.81
Regulation of allergic inflammation by the ectoenzyme E-NPP3 (CD203c) on basophils and mast cells. Semin Immunopathol (2016) 0.80
Basophil activation test: food challenge in a test tube or specialist research tool? Clin Transl Allergy (2016) 0.80
Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy (2014) 0.79
Lysis with Saponin improves detection of the response through CD203c and CD63 in the basophil activation test after crosslinking of the high affinity IgE receptor FcepsilonRI. Clin Mol Allergy (2005) 0.79
Role of basophils in rheumatoid arthritis (Review). Exp Ther Med (2015) 0.78
IgE-mediated 15-hydroxyeicosatetraenoic acid (15-HETE) generation by peripheral blood leukocytes: its association with basophil activation. Postepy Dermatol Alergol (2015) 0.78
Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. J Immunol (2015) 0.77
Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. Immunobiology (2013) 0.77
Monitoring Allergen Immunotherapy Effects by Microarray. Curr Treat Options Allergy (2016) 0.76
Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis. Allergy (2014) 0.75
Basophil activation by mosquito extracts in patients with hypersensitivity to mosquito bites. Cancer Sci (2015) 0.75
Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES. J Biol Chem (2016) 0.75
Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. PLoS One (2016) 0.75
Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro. PLoS One (2015) 0.75
Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. J Allergy Clin Immunol (2015) 0.75
Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. Allergy (2013) 0.75
Exploratory analysis of CD63 and CD203c expression in basophils from hazelnut sensitized and allergic individuals. Clin Transl Allergy (2016) 0.75
Road map for the clinical application of the basophil activation test in food allergy. Clin Exp Allergy (2017) 0.75
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 3.83
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells (2007) 3.39
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol (2006) 2.80
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica (2003) 2.17
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol (2012) 2.05
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol (2010) 1.98
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res (2011) 1.82
Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica (2008) 1.80
Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol (2010) 1.80
Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. J Invest Dermatol (2010) 1.78
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res (2004) 1.71
Degradation by stratum corneum proteases prevents endogenous RNase inhibitor from blocking antimicrobial activities of RNase 5 and RNase 7. J Invest Dermatol (2009) 1.70
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J (2002) 1.66
Mastocytosis: state of the art. Pathobiology (2007) 1.64
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Signal regulatory protein (SIRPalpha), a cellular ligand for CD47, regulates neutrophil transmigration. J Biol Chem (2002) 1.63
The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol (2004) 1.63
Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma (2005) 1.61
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60
Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation (2006) 1.59
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2002) 1.54
Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol (2003) 1.54
Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst (2011) 1.52
High sensitivity of CAP-FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy. J Allergy Clin Immunol (2012) 1.52
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood (2006) 1.50
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50
Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy. J Allergy Clin Immunol (2011) 1.49
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res (2005) 1.44
Wheat allergy in children evaluated with challenge and IgE antibodies to wheat components. Pediatr Allergy Immunol (2015) 1.44
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol (2010) 1.44
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma (2006) 1.42
Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. Immunol Cell Biol (2012) 1.41
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem Cells (2007) 1.39
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res (2003) 1.39
Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma (2006) 1.39
[Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. Wien Klin Wochenschr (2002) 1.38
High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol (2009) 1.37
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res (2002) 1.35
Comprehensive mutational profiling in advanced systemic mastocytosis. Blood (2013) 1.35
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica (2010) 1.27
Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol (2010) 1.25
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol (2004) 1.24
Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol (2005) 1.23
CD molecules 2006--human cell differentiation molecules. J Immunol Methods (2006) 1.23
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol (2014) 1.22
Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res (2005) 1.21
Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol (2006) 1.21
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res (2004) 1.18
Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol (2002) 1.17
Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma (2006) 1.16
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett (2007) 1.16
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol (2010) 1.16
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res (2007) 1.16
A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol (2011) 1.15
Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int Arch Allergy Immunol (2002) 1.15
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15